Performance Evaluation of Real-Q HBV Quantification Kit for HBV DNA by Real-Time PCR.
10.3343/kjlm.2006.26.6.442
- Author:
Sang Hyun HWANG
1
;
Choong Hwan CHA
;
Yoo Li KIM
;
Oh Joong KWON
;
Heung Bum OH
Author Information
1. Department of Laboratory Medicine, Pusan National University Hospital, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Real-time polymerase chain reaction;
Hepatitis B virus;
Evaluation;
TaqMan
- MeSH:
Cytomegalovirus;
DNA*;
Hepacivirus;
Hepatitis B virus;
HIV;
Humans;
Korea;
Limit of Detection;
Polymerase Chain Reaction;
Real-Time Polymerase Chain Reaction*;
Reproducibility of Results;
Sensitivity and Specificity
- From:The Korean Journal of Laboratory Medicine
2006;26(6):442-448
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Hepatitis B virus (HBV) DNA quantification is important for the management of HBV infection and identification of the development of resistance. The susceptibility to contamination and more variable reproducibility of results with the conventional HBV DNA quantification method have raised the need of a more simple and accurate method for HBV DNA quantification. Real-time quantitative PCR assays recently introduced in the laboratory can meet these needs. In this study, we evaluated the performance of the Real-Q HBV Quantification kit developed in Korea. METHODS: We evaluated the recovery of DNA extraction, the interference of internal control, an analytical sensitivity, specificity, and reproducibility, a clinical specificity, and a reportable range of the Real-Q HBV Quantification kit. The quantification result was also compared to that obtained by the Digene Hybrid-Capture II. RESULTS: The mean percent recovery was 108.6% and there was no interference with the internal control on DNA extraction. None of HIV, hepatitis C virus, or cytomegalovirus showed a cross-reactivity with HBV. This assay detected HBV DNA in a linear range from 10(2) to 10(10) copies/mL, with the detection limit of 56 copies/mL. The assay exhibited a low within-run CV (coefficient of variation) (8.7-11.9%), between-run CV (10.5-14.7%), and between-day CV (13.2-21.4%). No HBV DNA was detected in any of 100 samples without HBV, resulting in a clinical specificity of 100%. The levels of HBV DNA showed a good correlation with those determined with Digene Hybrid-Capture II (R2=0.9827). CONCLUSIONS: The Real-Q HBV Quantification kit showed a good analytical sensitivity, specificity, and high reliability with a broad reportable range. This assay should be clinically useful in managing patients with HBV infection.
